286 related articles for article (PubMed ID: 16039868)
21. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
Kaper F; Dornhoefer N; Giaccia AJ
Cancer Res; 2006 Feb; 66(3):1561-9. PubMed ID: 16452213
[TBL] [Abstract][Full Text] [Related]
22. Targeting mTOR signaling in lung cancer.
Marinov M; Fischer B; Arcaro A
Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
[TBL] [Abstract][Full Text] [Related]
23. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
[TBL] [Abstract][Full Text] [Related]
25. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
26. mTOR inhibitors in hematologic malignancies.
Dancey JE
Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
[TBL] [Abstract][Full Text] [Related]
27. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
Woodard J; Sassano A; Hay N; Platanias LC
Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
[TBL] [Abstract][Full Text] [Related]
28. Antineoplastic effect of proliferation signal inhibitors: from biology to clinical application.
Bertoni E; Salvadori M
J Nephrol; 2009; 22(4):457-62. PubMed ID: 19662600
[TBL] [Abstract][Full Text] [Related]
29. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel.
Faried LS; Faried A; Kanuma T; Nakazato T; Tamura T; Kuwano H; Minegishi T
Eur J Cancer; 2006 May; 42(7):934-47. PubMed ID: 16540312
[TBL] [Abstract][Full Text] [Related]
31. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
32. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
33. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
Panner A; Parsa AT; Pieper RO
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
[TBL] [Abstract][Full Text] [Related]
34. [Antitumoral effect of proliferation signal inhibitors].
Dumortier J
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
[TBL] [Abstract][Full Text] [Related]
35. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin.
Euvrard S; Ulrich C; Lefrancois N
Dermatol Surg; 2004 Apr; 30(4 Pt 2):628-33. PubMed ID: 15061847
[TBL] [Abstract][Full Text] [Related]
36. The pleiotropic effects of mTor inhibitors.
Ponticelli C
J Nephrol; 2004; 17(6):762-8. PubMed ID: 15593048
[TBL] [Abstract][Full Text] [Related]
37. NCCN Task Force Report: mTOR inhibition in solid tumors.
Figlin RA; Brown E; Armstrong AJ; Akerley W; Benson AB; Burstein HJ; Ettinger DS; Febbo PG; Fury MG; Hudes GR; Kies MS; Kwak EL; Morgan RJ; Mortimer J; Reckamp K; Venook AP; Worden F; Yen Y
J Natl Compr Canc Netw; 2008 Sep; 6 Suppl 5():S1-20; quiz S21-2. PubMed ID: 18926092
[TBL] [Abstract][Full Text] [Related]
38. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation.
Asano T; Yao Y; Zhu J; Li D; Abbruzzese JL; Reddy SA
Biochem Biophys Res Commun; 2005 May; 331(1):295-302. PubMed ID: 15845392
[TBL] [Abstract][Full Text] [Related]
39. Sirolimus-induced signaling modifications in Kaposi's sarcoma with resolution in a liver transplant recipient.
Ho CM; Huang SF; Hu RH; Ho MC; Wu YM; Lee PH
Clin Transplant; 2010; 24(1):127-32. PubMed ID: 19919613
[TBL] [Abstract][Full Text] [Related]
40. [Rapamycin and CCI-779].
Alexandre J; Raymond E; Armand JP
Bull Cancer; 1999 Oct; 86(10):808-11. PubMed ID: 10572230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
